UK-based drugmaker Indivior considers moving primary stock market listing to the US.

UK-based drugmaker Indivior is considering moving its primary stock market listing to the US, following other companies that have changed their primary listings to New York. The company's share price has soared 22% on news of the potential move, which could attract more investors and analysts, potentially leading to inclusion in major US indexes. Indivior plans to keep a secondary listing in the UK.